Literature DB >> 16483675

Involvement of the endocannabinoid system in drug addiction.

Rafael Maldonado1, Olga Valverde, Fernando Berrendero.   

Abstract

Recent studies have shown that the endocannabinoid system is involved in the common neurobiological mechanism underlying drug addiction. This system participates in the primary rewarding effects of cannabinoids, nicotine, alcohol and opioids, through the release of endocannabinoids in the ventral tegmental area. Endocannabinoids are also involved in the motivation to seek drugs by a dopamine-independent mechanism, demonstrated for psychostimulants and opioids. The endocannabinoid system also participates in the common mechanisms underlying relapse to drug-seeking behaviour by mediating the motivational effects of drug-related environmental stimuli and drug re-exposure. In agreement, clinical trials have suggested that the CB(1) cannabinoid antagonist rimonabant can cause smoking cessation. Thus, CB(1) cannabinoid antagonists could represent a new generation of compounds to treat drug addiction.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16483675     DOI: 10.1016/j.tins.2006.01.008

Source DB:  PubMed          Journal:  Trends Neurosci        ISSN: 0166-2236            Impact factor:   13.837


  184 in total

Review 1.  Cannabinoid CB1 receptor-interacting proteins: novel targets for central nervous system drug discovery?

Authors:  Tricia H Smith; Laura J Sim-Selley; Dana E Selley
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

Review 2.  Animal models of cannabinoid reward.

Authors:  Leigh V Panlilio; Zuzana Justinova; Steven R Goldberg
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

Review 3.  New insights on the role of the endocannabinoid system in the regulation of energy balance.

Authors:  B Gatta-Cherifi; D Cota
Journal:  Int J Obes (Lond)       Date:  2015-09-16       Impact factor: 5.095

4.  Genetic Versus Pharmacological Assessment of the Role of Cannabinoid Type 2 Receptors in Alcohol Reward-Related Behaviors.

Authors:  Matthew S Powers; Kristen R Breit; Julia A Chester
Journal:  Alcohol Clin Exp Res       Date:  2015-12       Impact factor: 3.455

5.  Behavioral effects of psychostimulants in mutant mice with cell-type specific deletion of CB2 cannabinoid receptors in dopamine neurons.

Authors:  Ana Canseco-Alba; Norman Schanz; Branden Sanabria; Juan Zhao; Zhicheng Lin; Qing-Rong Liu; Emmanuel S Onaivi
Journal:  Behav Brain Res       Date:  2018-11-30       Impact factor: 3.332

6.  Cannabinoid receptors CB1 and CB2 form functional heteromers in brain.

Authors:  Lucía Callén; Estefanía Moreno; Pedro Barroso-Chinea; David Moreno-Delgado; Antoni Cortés; Josefa Mallol; Vicent Casadó; José Luis Lanciego; Rafael Franco; Carmen Lluis; Enric I Canela; Peter J McCormick
Journal:  J Biol Chem       Date:  2012-04-24       Impact factor: 5.157

7.  Cross-sensitization and cross-tolerance between exogenous cannabinoid antinociception and endocannabinoid-mediated stress-induced analgesia.

Authors:  Richard L Suplita; Sarah A Eisenstein; Mark H Neely; Anna M Moise; Andrea G Hohmann
Journal:  Neuropharmacology       Date:  2007-07-19       Impact factor: 5.250

8.  CB1 antagonism: interference with affective properties of acute naloxone-precipitated morphine withdrawal in rats.

Authors:  Kiri L Wills; Kiran Vemuri; Alana Kalmar; Alan Lee; Cheryl L Limebeer; Alexandros Makriyannis; Linda A Parker
Journal:  Psychopharmacology (Berl)       Date:  2014-04-27       Impact factor: 4.530

9.  Short-term exposure to alcohol in rats affects brain levels of anandamide, other N-acylethanolamines and 2-arachidonoyl-glycerol.

Authors:  Marina Rubio; Douglas McHugh; Javier Fernández-Ruiz; Heather Bradshaw; J Michael Walker
Journal:  Neurosci Lett       Date:  2007-06-02       Impact factor: 3.046

Review 10.  The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.

Authors:  R G Pertwee
Journal:  Br J Pharmacol       Date:  2007-09-10       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.